Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Hanae Oshikiri"'
Autor:
Masaki Kumondai, Reika Ogawa, Nagomi Hayashi, Yurika Ishida, Hanae Oshikiri, Yuji Sato, Masafumi Kikuchi, Yu Sato, Toshihiro Sato, Masamitsu Maekawa, Nariyasu Mano
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 4, Pp n/a-n/a (2024)
Abstract Lenvatinib (LEN), a multitarget tyrosine kinase inhibitor used in various cancer treatments, is mainly metabolized by cytochrome P450 3A (CYP3A) enzymes. The importance of therapeutic drug monitoring (TDM) in patients administered LEN has be
Externí odkaz:
https://doaj.org/article/3c3b7eda38744636833b54cae65ec9d1
Autor:
Naoto Ishikawa, Hanae Oshikiri, Shinya Takasaki, Masafumi Kikuchi, Taku Obara, Kazutoshi Akasaka, Masaki Matsuura, Hiroaki Yamaguchi, Nariyasu Mano
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 7, Iss 1, Pp 1-6 (2021)
Abstract Background Renal function and use of concomitant medications should be carefully monitored in patients subjected to treatment with direct oral anticoagulants (DOACs); the dose should be individually designed for each patient. Owing to the co
Externí odkaz:
https://doaj.org/article/8fa8e76eeebb4069a6a8f8c9fc5b774b
Autor:
Manami Sasaki, Yuya Taguchi, Keita Tagami, Hanae Oshikiri, Takahiro Maejima, Yoko Nakajo, Maiko Kanazawa, Mamiko Sato, Mikiko Fuda, Akira Inoue
Publikováno v:
Palliative Care Research. 17:97-104
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ab074310d1b6164d4b2b592d41c3760
https://doi.org/10.2512/jspm.17.97
https://doi.org/10.2512/jspm.17.97
Autor:
Nariyasu Mano, Taku Obara, Shinya Takasaki, Masafumi Kikuchi, Masaki Matsuura, Hanae Oshikiri, Kazutoshi Akasaka, Naoto Ishikawa, Hiroaki Yamaguchi
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 7, Iss 1, Pp 1-6 (2021)
Journal of Pharmaceutical Health Care and Sciences
Journal of Pharmaceutical Health Care and Sciences
Background Renal function and use of concomitant medications should be carefully monitored in patients subjected to treatment with direct oral anticoagulants (DOACs); the dose should be individually designed for each patient. Owing to the complex the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42d88e6559fcf3bb64fe7c2e00935a53
https://doi.org/10.1186/s40780-021-00205-y
https://doi.org/10.1186/s40780-021-00205-y